title: Therapeutic effects of simvastatin on hyperlipidemia in CAPD patients.
abstract: A causal link between hypercholesterolemia due to elevated plasma concentrations of LDL and VLDL remnants of CAPD patients has been established. The effects of 24 weeks of treatment with Simvastatin, a new HMG coenzyme A-reductase inhibitor (at 20 and 40 mg/day) on serum lipid, lipoprotein, and apolipoprotein A-I and B concentrations, as well as safety parameters and subjective side effects, were evaluated in eight patients (mean duration CAPD 24.80 +/- 7.50 months, age 54.50 +/- 13.70 years). Maximal effects on plasma lipoprotein and apolipoprotein concentrations were achieved after 4 weeks, and remained stable thereafter during the study. Mean fasting plasma cholesterol concentrations decreased from 280.5 +/- 60.2 mg% to 190.2 +/- 40.4 mg/dl (p less than 0.005) (-47%); mean plasma LDL-cholesterol concentrations also decreased from 257.6 +/- 13.4 mg% to 190.5 +/- 15.4 mg/dl (p less than 0.001) (-35%). Apolipoprotein A and B concentrations decreased significantly from 1.78 +/- 0.19 to 1.40 +/- 0.22 g/L (p less than .005) and 1.81 +/- 0.26 to 1.38 +/- 0.20 g/L (p less than .005). These data substantiate the view that Simvastatin is well tolerated and that no serious clinical or adverse laboratory effects have been observed. It appears to be a promising drug for the effective control of hyperlipemia in a large proportion of hypercholesterolemic patients, reducing their cardiovascular morbidity while on CAPD.
authors: Institute of Nephrology, University of Chieti, Italy.
authors: B
authors: B
authors: Di Paolo
authors: G
authors: G
authors: Del Rosso
authors: G
authors: G
authors: Catucci
authors: V
authors: V
authors: Vocino
authors: M G
authors: MG
authors: Terenzio
authors: M
authors: M
authors: Bonomini
authors: K
authors: K
authors: Suriani
authors: A
authors: A
authors: Albertazzi
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents; D001053:Apolipoproteins / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000628:therapy; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D019821:Simvastatin
chemical_list: D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin; D019821:Simvastatin